-
The NEAT Predictive Model for Survival in Patients with Advanced Cancer
-
Amanda Zucker, Chiaojung Jillian Tsai, John Loscalzo, Pedro Calves, Johnny Kao
-
Cancer Res Treat. 2018;50(4):1433-1443. Published online January 24, 2018
-
DOI: https://doi.org/10.4143/crt.2017.223
-
-
 Abstract
 PDF PubReader ePub
- Purpose
We previously developed a model to more accurately predict life expectancy for stage IV cancer patients referred to radiation oncology. The goals of this study are to validate this model and to compare competing published models.
Materials and Methods
From May 2012 to March 2015, 280 consecutive patientswith stage IV cancerwere prospectively evaluated by a single radiation oncologist. Patients were separated into training, validation and combined sets. TheNEAT model evaluated number of active tumors (“N”), Eastern Cooperative Oncology Group performance status (“E”), albumin (“A”) and primary tumor site (“T”). The Odette Cancer Center model validated performance status, bone only metastases and primary tumor site. The Harvard TEACHH model investigated primary tumor type, performance status, age, prior chemotherapy courses, liver metastases, and hospitalization within 3 months. Cox multivariable analyses and logisticalregressionwere utilized to compare model performance.
Results
Number of active tumors, performance status, albumin, primary tumor site, prior hospitalizationwithin the last 3 months, and liver metastases predicted overall survival on uinvariate and multivariable analysis (p < 0.05 for all). The NEAT model separated patients into four prognostic groups with median survivals of 24.9, 14.8, 4.0, and 1.2 months, respectively (p < 0.001). The NEAT model had a C-index of 0.76 with a Nagelkerke’s R2 of 0.54 suggesting good discrimination, calibration and total performance compared to competing prognostic models.
Conclusion
The NEAT model warrants further investigation as a clinically useful approach to predict survival in patients with stage IV cancer.
-
Citations
Citations to this article as recorded by  - Nutritional care pathways in cancer patients with malignant bowel obstruction: A retrospective multi-centre study
Pinal S. Patel, Konstantinos Fragkos, Niamh Keane, David Wilkinson, Amy Johnson, Derek Chan, Bradley Roberts, Penny Neild, Metin Yalcin, Philip Allan, Michael E.B. FitzPatrick, Michael Gomez, Sarah Williams, Klaartje Kok, Lisa Sharkey, Carla Swift, Shamee
Clinical Nutrition ESPEN.2024; 59: 118. CrossRef - Predicting long‑term survival following involved site radiotherapy for oligometastases
Johnny Kao, Patricia Eckardt, Jennifer Mceachron, Christopher Atalla, Ashish Sangal
Oncology Letters.2024;[Epub] CrossRef - Palliative radiotherapy: survival prognostic factors - single-centre retrospective cohort study
Sian Cooper, Mary Denholm, Abdul Shawal Malek, Jeffrey Arun Rubasingham, David Tsang
BMJ Supportive & Palliative Care.2024; : spcare-2024-004810. CrossRef - Thirty‐day mortality after palliative radiotherapy in advanced cancer patients: Optimizing end‐of‐life care in Asia
Mi Sun Kim, Hyejung Cha, Sei Hwan You, Sunghyun Kim
Journal of Medical Imaging and Radiation Oncology.2024; 68(3): 307. CrossRef - Palliative Appropriateness Criteria: A Pragmatic Method to Evaluate the Suitability of Palliative Radiotherapy Fractionation
Joshua C. Farris, Adam G. Johnson, Patrick P. Carriere, Zachary A. Patel, Moeko Nagatsuka, Michael K. Farris, Ryan T. Hughes
Journal of Palliative Medicine.2023; 26(1): 67. CrossRef - The LabPS score
Carsten Nieder, Ellinor C. Haukland, Bård Mannsåker, Astrid Dalhaug
American Journal of Clinical Oncology.2023; 46(4): 178. CrossRef - Long-term disease-free survival following comprehensive involved site radiotherapy for oligometastases
Johnny Kao, Michelle Sahagian, Vani Gupta, Symeon Missios, Ashish Sangal
Frontiers in Oncology.2023;[Epub] CrossRef - Defining the expected 30-day mortality for patients undergoing palliative radiotherapy: A meta-analysis
Justin Henry Kutzko, Parvati Dadwal, Tanya Holt, Muhammed Aashiq Rahman, Syeda Farah Zahir, Brigid Hickey
Radiotherapy and Oncology.2022; 168: 147. CrossRef - Risk Stratification for Imminent Risk of Death at the Time of Palliative Radiotherapy Consultation
Susan Y. Wu, Emily Yee, Harish N. Vasudevan, Shannon E. Fogh, Lauren Boreta, Steve E. Braunstein, Julian C. Hong
JAMA Network Open.2021; 4(7): e2115641. CrossRef - Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review
André G. Gouveia, Dominic C.W. Chan, Peter J. Hoskin, Gustavo N. Marta, Fabio Trippa, Ernesto Maranzano, Edward Chow, Mauricio F. Silva
Radiotherapy and Oncology.2021; 163: 55. CrossRef - Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care
Matthew S. Ning, Prajnan Das, David I. Rosenthal, Bouthaina S. Dabaja, Zhongxing Liao, Joe Y. Chang, Daniel R. Gomez, Ann H. Klopp, G. Brandon Gunn, Pamela K. Allen, Paige L. Nitsch, Rachel B. Natter, Tina M. Briere, Joseph M. Herman, Rebecca Wells, Alber
Journal of the National Comprehensive Cancer Network.2021; 19(7): 805. CrossRef - Association of radiation dose intensity with overall survival in patients with distant metastases
Johnny Kao, Mark K. Farrugia, Samantha Frontario, Amanda Zucker, Emily Copel, John Loscalzo, Ashish Sangal, Boramir Darakchiev, Anurag Singh, Symeon Missios
Cancer Medicine.2021; 10(22): 7934. CrossRef - Palliative Radiotherapy
William Tristram Arscott, Jaclyn Emmett, Alireza Fotouhi Ghiam, Joshua A. Jones
Hematology/Oncology Clinics of North America.2020; 34(1): 253. CrossRef - Physician-Predicted Prognosis and Palliative Radiotherapy Treatment Utilization at the End of Life: An Audit of a Large Cancer Center Network
Adrianna E. Mojica-Márquez, Joshua L. Rodríguez-López, Ankur K. Patel, Diane C. Ling, Malolan S. Rajagopalan, Sushil Beriwal
Journal of Pain and Symptom Management.2020; 60(5): 898. CrossRef - External validation of life expectancy prognostic models in patients evaluated for palliative radiotherapy at the end‐of‐life
Adrianna E. Mojica‐Márquez, Joshua L. Rodríguez‐López, Ankur K. Patel, Diane C. Ling, Malolan S. Rajagopalan, Sushil Beriwal
Cancer Medicine.2020; 9(16): 5781. CrossRef - Replacing 30 Gy in 10 fractions with stereotactic body radiation therapy for bone metastases: A large multi-site single institution experience 2016–2018
Erin F. Gillespie, Kaitlyn Lapen, Diana G. Wang, N. Wijetunga, Gerri L. Pastrana, Marisa A. Kollmeier, Josh Yamada, Adam M. Schmitt, Daniel S. Higginson, Max Vaynrub, Ernesto Santos Martin, Amy J. Xu, C. Jillian Tsai, Divya Yerramilli, Oren Cahlon, T. Jon
Clinical and Translational Radiation Oncology.2020; 25: 75. CrossRef - Palliative radiotherapy near the end of life
Susan Y. Wu, Lisa Singer, Lauren Boreta, Michael A. Garcia, Shannon E. Fogh, Steve E. Braunstein
BMC Palliative Care.2019;[Epub] CrossRef - Blood Albumin As A Prognostic Factor Among Unselected Medically Treated Inpatients
Krzysztof Tojek, Gabriel Kowalczyk, Beata Czerniak, Wioletta Banaś, Beata Szukay, Wanda Korzycka-Wilińska, Zbigniew Banaszkiewicz, Jacek Budzyński
Biomarkers in Medicine.2019; 13(13): 1059. CrossRef
-
8,232
View
-
181
Download
-
23
Web of Science
-
18
Crossref
|
KCA
